Srra stock zacks
The Zacks Scorecard is a complimentary set of indicators to use alongside the Zacks Rank. It allows the investor to better focus on the stocks that are the best fit for his or her personal investment style. We produce five unique ratings, including the Zacks Style Score, which combines the individual style scores into 1 rating: Exploring Sierra Oncology (NASDAQ:SRRA) stock? View SRRA's stock price, price target, earnings, financials, forecast, insider trades, news, and SEC filings at MarketBeat. Sierra Oncology (NASDAQ:SRRA) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report released on Saturday, Zacks.com reports. The firm presently has a $0.25 target price on the biotechnology company’s stock. Zacks Investment Research upgraded shares of Sierra Oncology (NASDAQ:SRRA) from a hold rating to a buy rating in a research note issued to investors on Saturday morning, Zacks.com reports. They currently have $0.25 price objective on the biotechnology company’s stock. 11/14/2019 · Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 2 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.21. The reported EPS for the same quarter last year was $-0.21. Sierra Oncology, Inc., a clinical stage drug development company, is advancing targeted therapeutics for the treatment of patients with unmet medical needs in
Selected key stats of ProNAi Therapeutics, Inc. (SRRA) including 10 year stock price and latest news. Key stats provide selected financials for rapid company overview including revenues, marketcap, P/E ratio, debt and much more.
Stock quote for Sierra Oncology, Inc. Common Stock Common Stock (SRRA) with real-time last sale and extended hours stock prices, company news, charts, and research at Wall Street analysts expect that Sierra Oncology Inc (NASDAQ:SRRA) will announce earnings per share (EPS) of ($0.20) for the current fiscal quarter, Zacks reports. 8/30/2018 · Sierra Oncology, Inc. SRRA could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front. Recently, the 50 Day Moving Average for SRRA broke out below the 200 Day Simple Moving Average, suggesting short-term bearishness. Get breaking news and analysis on Sierra Oncology, Inc. (SRRA) stock, price quote and chart, trading and investing tools. Shares of Sierra Oncology Inc (NASDAQ:SRRA) have been given a consensus broker rating score of 1.00 (Strong Buy) from the two brokers that provide coverage for the company, Zacks Investment Research reports. Two equities research analysts have rated the stock with a strong buy recommendation. 60-Month Beta: Coefficient that measures the volatility of a stock's returns relative to the market (S&P 500). It is based on a 60-month historical regression of the return on the stock onto the return on the S&P 500. Price/Sales: Latest closing price divided by the last 12 months of revenue/sales per share.
12 Jun 2019 Net Inc stocks price quote with latest real-time prices, charts, financials, latest news, technical analysis and opinions. SRRA : 0.34 (+2.27%).
18 Dec 2019 CA $PDS this stock is the mother of weird price action. It never. $PDS alerted $1.2600 potential exit $1.3000 +3.17% $SRRA alerted $0.4800 Historical daily share prices for Loxo Oncology since 2014 adjusted for splits and dividends. Open, high, low The latest closing price for Loxo Oncology as of August 31, 2018 is 168.98. ProNAi Therapeutics (SRRA), Canada, $0.131B, 0.00. The Turning Point Therapeutics 52-week high stock price is 43.63, which is 0% above the current share ProNAi Therapeutics (SRRA), Canada, $0.051B, 0.00.
6/1/2018 · While we can never know for sure, it is pretty encouraging that estimates for SRRA have moved higher in the past few weeks, meaning that analyst sentiment is moving in the right way. Plus, the stock actually has a Zacks Rank #2 (Buy), so the recent move higher for this spotlighted company may definitely continue over the next few weeks.
6/1/2018 · While we can never know for sure, it is pretty encouraging that estimates for SRRA have moved higher in the past few weeks, meaning that analyst sentiment is moving in the right way. Plus, the stock actually has a Zacks Rank #2 (Buy), so the recent move higher for this spotlighted company may definitely continue over the next few weeks. They set an “outperform” rating and a $1.20 price objective on the stock. Finally, Zacks Investment Research raised Sierra Oncology from a “hold” rating to a “buy” rating and set a $0.25 target price on the stock in a research report on Saturday, November 9th. Shares of SRRA stock opened at $0.49 on Wednesday. Their average twelve-month price target is $1.20, suggesting that the stock has a possible upside of 258.42%. The high price target for SRRA is $1.20 and the low price target for SRRA is $1.20. There are currently 2 buy ratings for the stock, resulting in a consensus rating of "Buy."
Sierra Oncology Inc (NASDAQ:SRRA) saw a significant growth in short interest in the month of November. As of November 15th, there was short interest totalling 191,800 shares, a growth of 18.6% from the October 31st total of 161,700 shares. Currently, 0.3% of the shares of the company are sold short. Based on an average trading […]
15 Jul 2019 So before you buy or sell Sierra Oncology, Inc. (NASDAQ:SRRA), you may well That means that even when the share price was higher than
10 Dec 2019 Sierra Oncology Inc (NASDAQ:SRRA) traded down 13.6% during trading on Tuesday . The company traded as low as $0.43 and last traded at 3 Dec 2019 Two equities research analysts have rated the stock with a strong buy Inc (NASDAQ:SRRA) Given $3.00 Consensus Target Price by Analysts. These returns cover a period from January 1, 1988 through December 2, 2019. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month.